August 30, 2021 -- NeuExcell Therapeutics has raised more than $10 million in a series pre-A funding round led by Co-Win Ventures.
The company develops a gene therapy focused on neurodegenerative diseases. Its headquarters are in State College, PA, and Shanghai, China. With this round of funding, the company also announced that it has added two members to its board of directors: Dr. Xin Huang and Jonathan Sun.
The company has developed a neural repair technology through astrocyte-to-neuron conversion in vivo by introducing neural transcription factor(s) through adeno-associated virus-based gene therapy. NeuExcell's pipeline covers major neurodegenerative diseases such as stroke, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, traumatic brain injury, spinal cord injury, and glioma.
Copyright © 2021 scienceboard.net